STOCKS TELEGRAPH

Tag: Pre Market

  • Abits Group Inc. (ABTS) Faces Pre-market Plunge Amidst Broader Uncertainty

    Abits Group Inc. (NASDAQ: ABTS) found itself in the eye of the storm during Thursday’s trading session, with its stock plummeting by a staggering 6.6%. However, the real shockwave hit after the closing bell, as the pre-market session witnessed an alarming additional dip of 12.4%, sending the stock price crashing below the $0.70 mark.

    Investors were left scratching their heads as there was no apparent catalyst to justify this drastic decline, fueling concerns of an impending profit-taking spree in the days ahead. Despite the uncertainty looming over ABTS, bullish sentiments prevail for now, with investors cautiously riding the waves.

    Background to Abits

    The company, known for its engagement in Internet media marketing services in China and bitcoin mining ventures in the United States, has been a subject of mixed sentiments among investors. Operating the Games Channel of the Xinhua App, a venture developed in collaboration with the Xinhua New China News Agency, ABTS has had its fair share of ups and downs in the market.

    Market Speculation

    Social media platforms have been abuzz with chatter regarding ABTS, often dubbing it as a typical Chinese junk stock. This sentiment has added fuel to the fire, intensifying the skepticism surrounding the company’s future prospects. With the recent plunge in stock price, investors are closely monitoring the developments, hoping for some clarity amidst the ambiguity.

    Technical Assessment

    Analyzing ABTS’s historical performance sheds some light on the current predicament. Over the past 22 months, the stock has witnessed more negative fluctuations in its average monthly price, indicating a volatile trend. However, there’s a silver lining in the form of consistent positive changes in average monthly volume, showcasing sustained investor interest despite the rollercoaster ride.

    The past week saw ABTS experiencing bullish runs, riding on the coattails of the surging bitcoin prices attributed to the approaching halving event. During one such rally, ABTS surged from $0.56 to a high of $0.92, providing a glimmer of hope for investors. However, with the bitcoin frenzy subsiding, ABTS finds itself retracing its steps back to reality.

    Conclusion

    As ABTS braces for the turbulence ahead, investors remain cautiously optimistic, hoping for a turnaround amidst the stormy seas of uncertainty. With the spotlight firmly fixed on ABTS, all eyes are on the company’s next move in this high-stakes game of market volatility.

  • FedEx Corp. (FDX) Rockets Over 15% in Premarket with Positive Updates

    FedEx Corporation (NYSE: FDX) navigated a sluggish trajectory during regular trading hours on Thursday, modestly ascending by a mere 1.87% from its previous closing at $259.55 to $256. However, the landscape dramatically shifted in the early premarket hours, as eager investors propelled the stock skyward by an astounding 35%, breaching the coveted $300 threshold.

    FedEx Corp. stands as a titan in the corporate realm, specializing in a comprehensive array of services spanning transportation, e-commerce facilitation, and bespoke business solutions. Its operational architecture encompasses distinct segments, including FedEx Express, FedEx Ground, FedEx Freight, FedEx Services, and Corporate, Other, and Eliminations.

    Earnings Report Highlights

    In a late Thursday revelation, FedEx Corporation disclosed adjusted earnings of $3.86 per diluted share for the fiscal 2024 third quarter, eclipsing analyst prognostications of $3.45 per share. This stellar performance ignited a fervent surge in after-hours trading, showcasing investor confidence in the company’s fiscal prowess.

    Segmental Performance

    Despite prevailing macroeconomic headwinds, FedEx Express, the aerial and international arm, showcased resilience with bolstered operating results, attributed to strategic efficiency enhancements and judicious cost containment measures. Parallelly, FedEx Ground reported amplified operating results buoyed by diminished structural overheads and enhanced revenue yields. Conversely, FedEx Freight grappled with subdued performance due to diminished fuel surcharges and a contraction in shipment volume.

    Guidance and Strategic Imperatives

    In a testament to its sanguine outlook, FedEx revised its full-year fiscal 2024 guidance, elevating the upper and lower echelons of its earnings projection to a range of $17.25 to $18.25 per share. This recalibration underscores the company’s unwavering commitment to realizing substantial cost savings of $1.8 billion through its transformative DRIVE program.

    Share Repurchase Endeavor

    A pivotal catalyst propelling the stock’s meteoric ascent was the announcement of a formidable $5 billion share repurchase program, duly authorized by the esteemed board of FedEx. This strategic maneuver, complemented by extant authorization, underscores the organization’s fervent dedication to augmenting shareholder value and fortifying its financial standing.

    Conclusion

    In summation, FedEx Corporation’s resounding after-hours surge serves as a testament to its indomitable resilience, underscored by an exceptional earnings report and strategic initiatives poised to propel the company towards sustained growth and prosperity.

  • BYND Cannasoft Enterprises Inc. (BCAN) Surges Amid Cannabis Industry Optimism

    BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) faced a tumultuous Friday, with shares plummeting nearly 4%. However, the weekend ushered in a surprising turn of events, as BCAN rebounded spectacularly, surging by an impressive 8.14% in the premarket hours.

    Background

    Established as an Israeli-based integrated software and cannabis company, BYND Cannasoft boasts a diverse portfolio, including the proprietary customer relationship management (CRM) software “Benefit CRM.”

    This innovative tool streamlines the operations of small and medium-sized businesses, offering solutions for sales management, personnel management, marketing, call center activities, and asset management. Leveraging two decades of CRM expertise, BYND Cannasoft is pioneering a cutting-edge CRM platform tailored for the medical cannabis industry, aiming to enhance market organization, accessibility, and price transparency.

    Notably, BCAN holds the patent-pending intellectual property for the EZ-G device, a therapeutic innovation designed for women’s health. Integrating proprietary software, this device administers controlled doses of CBD oil and other natural oils to address various health concerns. Moreover, its advanced features, including a Bluetooth-controlled app and AI integration, promise personalized user experiences.

    Marijuana Industry Connection

    BCAN’s fortunes are intertwined with the burgeoning marijuana industry. Recent market activity reflects this trend, with cannabis stocks experiencing notable gains. AdvisorShares Pure US Cannabis ETF surged by 9%, reflecting investor optimism fueled by speculation surrounding regulatory changes. Dougie Kass’s revelation on social media platform X hinted at potential DEA reclassification of marijuana, sparking a bullish sentiment across the sector.

    Key players in the U.S. cannabis market, such as Curaleaf, Green Thumb Industries, Verano Holdings, and Trulieve Cannabis, observed significant upticks in share value, signaling widespread market confidence. These developments coincide with Secretary Xavier Becerra’s testimony, underscoring the ongoing regulatory scrutiny of cannabis scheduling.

    Conclusion

    In conclusion, BYND Cannasoft’s resilience amidst market fluctuations underscores its strategic positioning within the cannabis and software sectors. As regulatory landscapes evolve, BCAN remains poised to capitalize on emerging opportunities, driving innovation and growth within the dynamic cannabis market.

  • Solidion Technology Inc. Rockets in Premarket, Surging 76% in Two Days

    Solidion Technology Inc. (NASDAQ: STI) has set the stock market ablaze with its astonishing performance over the weekend, building upon Friday’s already impressive gains. The company’s shares witnessed a remarkable surge of 34% during regular trading hours on Friday, but it didn’t stop there.

    Over the weekend, investor optimism soared even higher, propelling STI to an additional 42% gain in the premarket, bringing the total increase to a staggering 76% in just two days. As of the latest data, Solidion’s stock is poised at the cusp of the $2.50 mark, marking a significant milestone for the Dallas-based firm.

    Strategic Diversification: Solidion’s Niche in Battery Technology

    Based in Dallas, Texas, and boasting operational facilities in Dayton, Ohio, Solidion Technology Inc. specializes in the intricate realm of battery technology. Their core focus spans the manufacturing of battery materials and components, alongside the development and production of cutting-edge batteries tailored for a diverse range of applications, including energy storage systems and electric vehicles across ground, air, and sea transportation.

    Distinguishing itself through innovation, Solidion offers a comprehensive suite of battery products, encompassing advanced anode materials and a trio of solid-state battery classes. These batteries, featuring advanced polymer-based solid electrolytes, not only promise scalability in production but also deliver superior safety and performance metrics, including extended range and reduced costs per kilowatt-hour (KWh).

    Financial Maneuvers: Solidion’s Strategic Investment and Expansion Plans

    In a strategic move aimed at bolstering its financial standing and supporting future growth initiatives, Solidion recently announced a securities purchase agreement with institutional investors.

    This agreement is slated to raise approximately $3.85 million in cash proceeds, underscoring investor confidence in the company’s strategic direction and growth prospects. With the private placement set to conclude on March 14, 2024, Solidion is poised to strengthen its financial foundation and propel its expansion plans forward.

    Future Outlook: Solidion’s Path to Sustainable Growth

    Solidion’s rapid ascent and strategic initiatives underscore its position as a frontrunner in the dynamic landscape of battery technology. With a steadfast commitment to innovation, sustainability, and strategic partnerships, the company is poised to capitalize on the escalating demand for advanced battery solutions, particularly within the electric vehicle segment.

    As global demand for battery materials continues to soar, Solidion stands ready to navigate the challenges and seize the opportunities that lie ahead, promising a bright and sustainable future for the company and its stakeholders.

  • C3is Inc. (CISS) Seeks to Rebound in Premarket Following Hard Plunge

    C3is Inc. (NASDAQ: CISS) underwent a tumultuous journey on Friday as its stock price nosedived by a staggering 65%, causing widespread concern among investors. However, a glimmer of hope emerged during the weekend when the premarket hours witnessed a modest 12% uptick, albeit insufficient to offset the previous day’s losses.

    The Delisting Dilemma

    The drastic plunge in CISS’s stock value appears to be intricately tied to a potential delisting threat looming over the company. A stern notification from The Nasdaq Stock Market LLC surfaced on Friday, revealing that CISS’s common stock had persistently traded below the crucial threshold of $0.10 for ten consecutive days, triggering concerns under Nasdaq Listing Rule 5810(c)(3)(A)(iii).

    Consequently, the company faces the grim prospect of delisting unless a successful appeal is lodged by March 22, 2024.

    Navigating Through Uncertainty

    In response to the imminent delisting menace, C3is Inc. swiftly moved to challenge the Nasdaq Staff Determination, opting for a formal hearing before a Nasdaq Hearings Panel. This strategic maneuver invokes a temporary reprieve from delisting until the panel reaches a verdict, a process typically spanning 30-45 days post-appeal. Meanwhile, CISS’s common stock will persist in trading on the Nasdaq Capital Market under the familiar symbol “CISS.”

    Moreover, CISS grapples with non-compliance under Nasdaq Rule 5550(a)(2), compounded by its shares lingering below $1.00 for thirty consecutive trading days. Despite the looming shadows, the company maintains a resilient stance, contemplating diverse strategies, including a potential reverse stock split, to address the looming compliance challenges.

    Looking Ahead

    As the clock ticks towards the pivotal March 22 appeal deadline, stakeholders closely monitor CISS’s trajectory amidst speculation and apprehension.

    Amidst the prevailing turbulence, voices of optimism resonate, citing the company’s robust balance sheet anchored by $40 million in assets and an absence of long-term debt. With a current market capitalization of $800,000 seemingly disproportionate to its intrinsic value, anticipation brews for a potential resurgence, underpinning hopes for a resilient bounce-back in the face of adversity.

  • Jet.AI Inc. (JTAI) Shifts Gears & Rockets 35% in Pre-market

    Jet.AI Inc. (NASDAQ: JTAI) experienced a tumultuous journey in yesterday’s trading session, witnessing a sharp decline from $0.85 to $0.66. However, the premarket hours today painted a drastically different picture, as the stock soared by an impressive 35%, surging past the $0.91 mark. This unexpected surge has left market participants intrigued and scrambling for explanations.

    Market Speculation and Trading Activity

    Despite the lack of concrete news driving the premarket surge, investors remain optimistic about Jet.AI’s prospects, evidenced by increased trading volume. Many market participants interpret this surge as an opportunity to capitalize on the recent dip, driving buying interest and pushing the stock’s volume slightly higher than average.

    While the sudden surge has elicited excitement among bulls, some investors remain cautious, anticipating a potential profit-taking dip in the coming days. The absence of substantial news backing the pump adds an element of uncertainty to the stock’s short-term trajectory. However, for now, bullish sentiment prevails as investors eagerly ride the momentum.

    The Company’s Operations

    Founded in 2018 by Michael Winston, Jet.AI is a Delaware corporation deeply involved in various aspects of the private aviation industry. The company facilitates the sale of fractional and whole interests in aircraft, operates jet card programs, and manages a proprietary booking platform, among other services. Jet.AI’s business model encompasses aircraft brokerage, chartering, and service revenue from aircraft management.

    Jet.AI’s fractional ownership program allows customers to purchase ownership shares in jets, granting access for a preset number of hours annually. Additionally, the company’s jet card program offers customers fixed hourly rates for private jet access over agreed-upon terms. Revenue streams include sales of fractional interests, jet cards, and commissions from third-party charters.

    Conclusion

    In conclusion, Jet.AI’s dramatic premarket movement underscores the volatile nature of the stock market, with sentiment often swaying rapidly in response to various factors. As the trading day unfolds, all eyes will be on Jet.AI as investors continue to dissect the implications of its remarkable surge.

  • Geron Corporation (GERN) Surges 80% Following Favorable FDA Ruling

    Geron Corporation (NASDAQ: GERN) experienced a remarkable surge in premarket trading, with its stock skyrocketing by an impressive 80%. This surge comes on the heels of a static, zero-movement day on Thursday, indicating a sudden and significant shift in investor sentiment.

    The heightened interest in Geron can be attributed to a favorable ruling from the Food and Drug Administration (FDA), marking a pivotal moment for the biotech company.

    FDA Advisory Committee Vote

    Geron recently faced scrutiny over its blood cancer drug candidate, imetelstat, amid questions regarding its benefit-risk profile. However, the company emerged victorious as the FDA advisory committee voted 12 to 2 in favor of the drug. This decisive outcome triggered a surge in Geron’s share price, reflecting investor optimism about the potential of imetelstat.

    Additionally, there is a prevailing belief in the market that Geron is undervalued, with Goldman Sachs previously setting a price target of $6 for the stock. The significant short float of 10% further underscores the disappointment among short sellers following the recent update.

    Expert Opinions and Market Outlook

    Dr. Neil Vasan of Columbia University Medical Center expressed confidence in imetelstat, emphasizing its significance for patients with limited treatment options. While acknowledging the concerns raised by some experts, including Dr. Ravi Madan of the National Cancer Institute and Dr. Christopher Lieu of the University of Colorado, Dr. Vasan highlighted the benefits of achieving transfusion independence for certain patients.

    Despite differing opinions among experts, the overall sentiment surrounding Geron’s prospects remains positive. Investors are anticipating regulatory authorization from the FDA, with a decision expected by June 16. This optimism is reflected in the surge of Geron’s stock in premarket trading, pushing its value above $3.20.

    Conclusion

    Geron Corporation’s surge in premarket trading underscores the significance of the FDA’s favorable ruling on its blood cancer drug candidate, imetelstat.

    Despite concerns raised by some experts, the majority vote in favor of the drug signals a potential breakthrough for Geron. With regulatory authorization pending, investors are optimistic about the company’s future prospects, driving its stock price higher in premarket trading.

  • Biotech LianBio (LIAN) to Cease Operations, Brings on Premarket Plummet

    LianBio (NASDAQ: LIAN) experienced an unexpected plummet in premarket trading, plunging by nearly 96%, with recent grim announcements. The company’s shares, which had sluggishly climbed merely by 0.81% on Thursday, witnessed a drastic fall in premarket hours, leaving investors bewildered.

    Just over a month ago, LianBio, a prominent Chinese biotech firm, conceded to the inevitable, declaring a conclusive end to its operations after a comprehensive four-month strategic review. Despite this decision looming, the company’s stock demonstrated a curious ascent, rising by 3% over the past month.

    A Rough History

    The departure of LianBio’s CEO and CFO in December 2023 foreshadowed a turbulent trajectory for the biotech, further accentuated by the rejection of a buyout proposal from Concentra Biosciences. Opting against the acquisition bid, LianBio took a definitive step towards winding down operations, concurrently initiating asset liquidation proceedings.

    This decisive move, announced last month, aims to expedite the dissolution process, anticipating completion by the end of the year, though the final dissolution is anticipated closer to 2027.

    Evidently, LianBio has been progressively divesting its assets, relinquishing rights to significant pharmaceuticals such as mavacamten and NBTXR3 to industry giants Bristol Myers Squibb and Johnson & Johnson, respectively. The impending staff reductions, with 50 full-time positions set to be axed by the end of March, signify the gravity of the company’s decision.

    Prioritizing Shareholder Interests

    In a proactive bid to uphold shareholder interests, LianBio plans to distribute proceeds from asset sales and extend a special cash dividend totaling $528 million to its American depository share holders. Notwithstanding these measures, the company cautions against expecting full recovery of investments, reflecting the precarious financial landscape it navigates.

    The abrupt denouement of LianBio, once poised to carve a niche in the biopharmaceutical landscape, underscores the capricious nature of the sector. Amidst a backdrop of failed buyout overtures and executive exodus, the decision to wind down operations reverberates through the market, prompting analysts to scrutinize the implications for the broader biotech industry.

    Conclusion

    With the lingering uncertainties, bearish sentiments persist, anchored on the belief that LianBio’s current valuation remains below its potential liquidation worth, hinting at no opportunities amid the tumultuous market landscape. Overall, it seems that the bears believe there is no gain to be made from the LIAN stock.

  • Spero Therapeutics, Inc. (SPRO) Sees Surge in Pre-Market Trading

    Spero Therapeutics, Inc. (NASDAQ: SPRO), a pioneering biopharmaceutical company specializing in treatments for bacterial infections and rare diseases, experienced a remarkable pre-market surge on Thursday, following a static day on Wednesday. The stock exhibited a sudden climb of 15%, indicating significant investor interest. This surge appears to be directly linked to the recent earnings release.

    The company, founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and headquartered in Cambridge, MA, boasts a robust pipeline of product candidates including Tebipenem HBr, SPR720, and SPR206. Spero Therapeutics has been making strides in its development-stage assets, as highlighted in a recent statement by CEO, Sath Shukla.

    Optimism from CEO

    The CEO, Sath Shukla, expressed enthusiasm about the progress across the company’s portfolio, particularly highlighting the advancements in the Tebipenem HBr program, now in late-stage proof of concept studies. Additionally, the recent FDA clearance for SVR to six, a treatment for hospital-acquired or ventilator-associated pneumonia, further strengthens the company’s position.

    Of particular interest is Spero’s SPR720 program, aimed at addressing nontuberculous mycobacterial pulmonary disease (NTMPD). With approximately 245,000 diagnosed patients in developed markets, NTMPD presents a significant unmet medical need. SPR720, an oral drug with a novel mechanism of action, has shown promising results in early studies, demonstrating potency against multiple NTM pathogens and minimal resistance development.

    Positive Collaboration

    Furthermore, Spero’s collaboration with partners like GSK for carbapenem HBr and Pfizer for SPR206 underscores its commitment to addressing various infectious diseases.

    Esther Rajavelu, the company’s financial executive, provided insights into Spero’s financial standing, highlighting significant revenue growth primarily attributed to collaboration agreements with GSK and Pfizer. The company’s prudent financial management ensures sufficient funding for operational and capital needs well into late 2025.

    Conclusion

    In conclusion, Spero Therapeutics, Inc.’s remarkable surge in pre-market trading reflects growing investor confidence fueled by positive developments in its pipeline and financial stability. With promising candidates in its arsenal and a steadfast commitment to addressing critical medical needs, Spero remains a key player in the biopharmaceutical landscape.

  • Ocean Power (OPTT) Shows Significant Pre-Market Jump with Q3 Results

    Ocean Power Technologies, Inc. (NYSE: OPTT) had a rather quiet trading day on Wednesday, with not much movement to speak of, experiencing a slight decrease of 0.78%. However, the mood swiftly changed in the pre-market trading session, witnessing an impressive surge of over 4.13%.

    Financial Results Propel Investor Excitement

    This pre-market surge appears to be intricately linked to the recent disclosure of OPTT’s financial performance for the third quarter of fiscal year 2024. OPTT disclosed robust financial figures, demonstrating substantial year-over-year growth across various key metrics.

    During the third quarter, OPTT saw a significant uptick in its pipeline, which soared to approximately $77 million, marking an impressive 5.5x increase compared to the same period last year. This surge in pipeline growth is indicative of OPTT’s expanding opportunities in the defense and security sector, as well as its burgeoning commercial prospects.

    Furthermore, OPTT showcased a noteworthy improvement in its gross margin rate, reaching 45.4% for the quarter, compared to 18.5% in the prior year. This positive trajectory in gross margin signals enhanced operational efficiency and profitability for the company.

    Strategic Moves and Contract Wins

    OPTT’s recent strategic initiatives and contract wins have further buoyed investor confidence. The company secured a substantial subcontract worth up to $6.5 million from a U.S. based prime contractor for the deployment of maritime domain awareness buoys, highlighting its dedication to national security initiatives.

    Additionally, OPTT received funding from the Naval Postgraduate School for the deployment of a PowerBuoy® in Monterey Bay, California. This deployment aims to showcase OPTT’s advanced maritime surveillance and communications capabilities.

    Moreover, OPTT announced multiple orders for its WAM-V Unmanned Surface Vehicles (USVs), totaling over $1.25 million, indicating growing demand for its innovative marine robotics solutions.

    Conclusion

    The surge in OPTT’s pre-market trading activity reflects investor enthusiasm following the company’s robust financial performance and strategic advancements.

    With a strong pipeline, improving gross margins, and key contract wins, OPTT appears poised for sustained growth in the maritime industry. As OPTT continues to execute its strategic roadmap, investors remain optimistic for further value creation and market expansion.